Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity.

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes, Obesity & Metabolism Pub Date : 2025-06-02 DOI:10.1111/dom.16466

Man Tang, Lizheng Shi, Dawei Guan, Debra Winberg, Tiange Tang, Hui Shao, Vivian Fonseca

{"title":"Long-term cost-effectiveness of tirzepatide for individuals with type 2 diabetes and comorbid obesity.","authors":"Man Tang, Lizheng Shi, Dawei Guan, Debra Winberg, Tiange Tang, Hui Shao, Vivian Fonseca","doi":"10.1111/dom.16466","DOIUrl":null,"url":null,"abstract":"Objectives: This study evaluates the cost-effectiveness of tirzepatide (TZP) 10 and 15 mg once weekly (QW) compared to placebo among individuals with type 2 diabetes (T2D) and comorbid obesity in the United States (US).Research design and methods: The Building, Relating, Assessing and Validating Outcomes (BRAVO) Diabetes Model was used to assess the cost-effectiveness of the two TZP doses in individuals with T2D and comorbid obesity from the US healthcare perspective, using a 30-year time horizon. Treatment effects were derived from the SURMOUNT-2 trial and assumed to persist for 5 years. Cost estimates were based on trial data and medication prices from GoodRx. Health utilities for diabetes-related complications were obtained from existing literature. One-way sensitivity analysis and probability sensitivity analysis (PSA) were conducted to examine the robustness. The willingness-to-pay (WTP) threshold was set at $100 000 per quality-adjusted life year (QALY) gained.Results: Compared with placebo, TZP 15 mg QW gained 0.69 QALYs, 0.58 life-years and a cost saving of $1409. TZP 10 mg QW gained 0.60 QALYs, 0.49 life-years and increased costs by $1855, resulting in an incremental cost-effectiveness ratio (ICERs) of $3092 per QALY. Sensitivity analysis confirmed the robustness of results. The probability of cost-effectiveness was 98.9% for TZP 15 mg QW and 98.9% for TZP 10 mg QW had 98.5%.Conclusion: Compared with placebo, both TZP 15 mg and 10 mg QW are cost-effective options for individuals with T2D and comorbid obesity.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16466","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study evaluates the cost-effectiveness of tirzepatide (TZP) 10 and 15 mg once weekly (QW) compared to placebo among individuals with type 2 diabetes (T2D) and comorbid obesity in the United States (US).

Research design and methods: The Building, Relating, Assessing and Validating Outcomes (BRAVO) Diabetes Model was used to assess the cost-effectiveness of the two TZP doses in individuals with T2D and comorbid obesity from the US healthcare perspective, using a 30-year time horizon. Treatment effects were derived from the SURMOUNT-2 trial and assumed to persist for 5 years. Cost estimates were based on trial data and medication prices from GoodRx. Health utilities for diabetes-related complications were obtained from existing literature. One-way sensitivity analysis and probability sensitivity analysis (PSA) were conducted to examine the robustness. The willingness-to-pay (WTP) threshold was set at $100 000 per quality-adjusted life year (QALY) gained.

Results: Compared with placebo, TZP 15 mg QW gained 0.69 QALYs, 0.58 life-years and a cost saving of $1409. TZP 10 mg QW gained 0.60 QALYs, 0.49 life-years and increased costs by $1855, resulting in an incremental cost-effectiveness ratio (ICERs) of $3092 per QALY. Sensitivity analysis confirmed the robustness of results. The probability of cost-effectiveness was 98.9% for TZP 15 mg QW and 98.9% for TZP 10 mg QW had 98.5%.

Conclusion: Compared with placebo, both TZP 15 mg and 10 mg QW are cost-effective options for individuals with T2D and comorbid obesity.

查看原文本刊更多论文

替西肽对2型糖尿病合并肥胖患者的长期成本效益

目的：本研究在美国2型糖尿病（T2D）和共病性肥胖患者中评估替西肽（TZP） 10和15mg （QW）与安慰剂相比的成本效益。研究设计和方法：采用建立、关联、评估和验证结果（BRAVO）糖尿病模型，从美国医疗保健的角度评估两种TZP剂量对T2D和合并症肥胖患者的成本效益，时间跨度为30年。治疗效果来源于SURMOUNT-2试验，并假定持续5年。成本估算基于GoodRx的试验数据和药物价格。从现有文献中获得糖尿病相关并发症的医疗效用。采用单因素敏感性分析和概率敏感性分析（PSA）检验稳健性。支付意愿（WTP）的门槛设定为每获得质量调整生命年（QALY） 10万美元。结果：与安慰剂相比，TZP 15 mg QW增加了0.69个qaly， 0.58个生命年，节省了1409美元的成本。TZP 10 mg QW增加了0.60个QALY， 0.49个生命年，增加了1855美元的成本，导致每个QALY的增量成本效益比（ICERs）为3092美元。敏感性分析证实了结果的稳健性。15 mg QW的成本-效果概率为98.9%，10 mg QW的成本-效果概率为98.5%。结论：与安慰剂相比，TZP 15mg和10mg QW对于T2D和合并症肥胖患者都是具有成本效益的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.